Medacta Group SA · SIX:MOVE

Medacta Group SA — FY2021 Earnings Presentation

14 slides from Medacta Group SA's earnings presentation, Jan 20, 2022

  1. Slide 1: FY 2021 Preliminary Unaudited Top-Line Figures

    FY 2021 PRELIMINARY UNAUDITED TOP-LINE FIGURES 20 January 2022

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on ou

  3. Slide 3: Presenters: Francesco Siccardi and Corrado Farsetta

    FRANCESCO SICCARDI CORRADO FARSETTA Chief Executive Officer Chief Financial Officer FY 2021 Preliminary Unaudited Top-Line Figures

  4. Slide 4: Highlights

    HIGHLIGHTS FY 2021 Revenue1 Revenue Growth vs FY20 Euro 363.1 million 21.4% at constant currency 20.0% reported Positive revenue contribution from all business lines Significant carry-over and customer acquisition, in and geographies addition to normalization of surgical activities, which were limit

  5. Slide 5: Deployment of the NextAR AR Surgical Platform

    DEPLOYMENT OF THE NEXTAR™ AR SURGICAL PLATFORM  NextAR, our Augmented Reality Surgical Platform, empowers the surgeon’s vision with real-time surgical guidance superimposed onto the operative field to make data-driven decision-making  All NextAR Platform applications for knee, shoulder and spine s

  6. Slide 6: Innovation and Product Development

    INNOVATION AND PRODUCT DEVELOPMENT  Hip – Further enhancement of the AMIS® (Bikini) technique – Expansion of revision systems – As innovative technologies, personalized solutions with 3D preoperative planning and intraoperative verification (MyHip® Planner and MyHip® Verifier)  Knee – Continuous f

  7. Slide 7: Marketing and Medical Education Programs

    MARKETING AND MEDICAL EDUCATION PROGRAMS  Medical Educations back to normal level with significant increase compared to 2019  Decentralized marketing and educational activities proved to be very effective at engaging surgeons and supporting customer acquisition  Further strengthening of the M.O.R

  8. Slide 8: Revenue Trend by Semester

    REVENUE TREND BY SEMESTER (€m) 21.4% 20.0% 35.4% 10.1%  In 2H 2021 elective surgeries were limited by the resurgence of Covid-19  The 2H 2020 comparative period already benefited from previous pent-up demand in certain geographies Notes: U stands for Unaudited figures 8

  9. Slide 9: FY Revenue Bridge by Product Line

    FY REVENUE1 BRIDGE BY PRODUCT LINE (€m) 17.8% 24.8% 35.4% 20.4% 21.4% 20.0% (€m) 19.0; 33.8; 5% 9% 179.3; 131.1; 50% 36% 2 Hip Knee Extremities Spine  Hip: growth driven by the AMIS® strategy supported by the roll-out of new products  Knee: good momentum generated by Kinematic Alignment, Efficienc

  10. Slide 10: FY Revenue Bridge by Geographic Area

    FY REVENUE1 BRIDGE BY GEOGRAPHIC AREA (€m) 21.2% 21.9% 17.5% 50.3% 21.4% 20.0% (€m) 12.6; 4% 84.9; 23% 156.4; 43% 109.2; 30% Europe NA APAC ROW  Europe: solid growth across all countries despite Covid-19 restrictions in Q1 and Q4  North America: customer acquisition, salesforce expansion and incre

  11. Slide 11: Thank you to all our Employees, Customers and Suppliers

    A great thank you to all our Employees for their commitment, resilience, and performance, and to our Customers and Suppliers for their collaboration and support in this challenging time 11

  12. Slide 12: Q&A

    Q&A FY 2021 Preliminary Unaudited Top-Line Figures

  13. Slide 13: Thank you for your attention

    Thank you for your attention Adedacta 44.0.R.E.

  14. Slide 14: Adedacta

    Adedacta International Adedacta 44.0.R.E.

Medacta Group — FY2021 Earnings Presentation on 6ix